Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

European Journal of Cancer

Volumn 42, Issue 4, 2006, Pages 548-556

  Strumberg, D ^a,e   Awada, A ^b   Hirte, H ^c   Clark, J W ^d   Seeber, S ^a   Piccart, P ^b   Hofstra, E ^e   Voliotis, D ^f   Christensen, O ^f   Brueckner, A ^g   Schwartz, B ^h  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b JULES BORDET INSTITUTE   (Belgium)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f BAYER AG   (Germany)

^g BAYER PHARMA AG   (Germany)

^h BAYER CORPORATION   (United States)

Author keywords

BAY 43 9006; PDGFR inhibitor; Phase I studies; Pooled analysis; Raf kinase inhibition; Refractory solid tumours; Sorafenib; VEGFR inhibitor

Indexed keywords

BILIRUBIN; PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER GRADING; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOOT DISEASE; HAND DISEASE; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; RASH; SKIN MANIFESTATION; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; STOMATITIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRIDINES; TREATMENT OUTCOME;

EID: 32444439875     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.11.014     Document Type: Article

References (30)

1. J. Downward Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 2003 11 22
2. W. Kolch, A. Kotwaliwale, and K. Vass The role of Raf kinases in malignant transformation Exp Rev Mol Med 2002 1 18
3. M.S. Brose, P. Volpe, and M. Feldman BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 2002 6997 7000
4. P. Dasgupta, J. Sun, and S. Wang Disruption of the Rb-Raf-1 interaction inhibits tumour growth and angiogenesis Mol Cell Biol 24 2004 9527 9541
5. E. Domingo, P. Laiho, and M. Ollikainen BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing J Med Genet 41 2004 664 668
6. G. Salvatore, R. Giannini, and P. Faviana Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma J Clin Endocrinol Metab 89 2004 5175 5180
7. M. Macaluso, G. Russo, and C. Cinti Ras family genes: an interesting link between cell cycle and cancer J Cell Physiol 192 2002 125 130
8. R.J. Slebos, R.E. Kibbelaar, and O. Dalesio K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung New Engl J Med 323 1990 561 565
9. H.J. Andreyev, A.R. Norman, and D. Cunningham Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J Natl Cancer Inst 90 1998 675 684
10. N.A. Lokker, C.M. Sullivan, and S.J. Hollenbach Platelet-derived growth factor (PDGF) autocrine signalling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumours Cancer Res 62 2002 3729 3735
11. A.M. Doanes, D.D. Hegland, and R. Sethi VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases Biochem Biophys Res Commun 255 1999 545 548
12. R.S. Herbst ZD1839: targeting the epidermal growth factor receptor in cancer therapy Expert Opin Invest Drugs 11 2002 837 849
13. N. Ferrara, K.J. Hillan, and H.P. Gerber Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400
14. N.H. Fernando, and H.I. Hurwitz Targeted therapy of colorectal cancer: clinical experience with bevacizumab Oncologist 9 Suppl. 1 2004 11 18
15. R.S. Herbst Targeted therapy using novel agents in the treatment of non-small-cell lung cancer Clin Lung Cancer 3 Suppl. 1 2002 S30 S38
16. E. Susman Rash correlates with tumour response after cetuximab Lancet Oncol 5 2004 647
17. R. Perez-Soler Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 17 2003 23 28
18. J.F. Lyons, S. Wilhelm, and B. Hibner Discovery of a novel Raf kinase inhibitor Endocr Relat Cancer 8 2001 219 225
19. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral anti-tumour activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis Cancer Res 64 2004 7099 7109
20. C. Gianpaolo-Ostravage, C. Carter, and B. Hibner Anti-tumour efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumour xenograft models Proc Am Assoc Cancer Res 42 2001 923
21. D. Strumberg, A. Awada, and P. Piccart Final report of the multiple single agent phase I clinical trials of the novel Raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumours Proc Am Soc Clin Oncol 22 2003 [Abstract 813]
22. D. Strumberg, H. Richly, and R.A. Hilger Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumours J Clin Oncol 23 2005 965 972
23. A. Awada, A. Hendlisz, and T. Gil Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: a promising anti-tumour agent Eur J Cancer 38 Suppl. 7 2002 S52 [Abstract 162]
24. Strumberg D, Voliotis D, Brendel E. A clinical phase I and biomarker study of the raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumours. Presented at AACR-NCI-EORTC; 2002.
25. H. Hirte, M. Moore, and S.J. Hotte Final results of a phase I study of the raf-1 kinase inhibitor BAY43-9006 in patients with advanced refractory solid tumours Eur J Cancer 38 Suppl. 7 2002 S55 [Abstract 173]
26. S.J. Hotte, and H.W. Hirte BAY 43-9006: early clinical data in patients with advanced solid malignancies Curr Pharm Des 8 2002 2249 2253
27. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
28. K.N. Meadows, P. Bryant, and K. Pumiglia Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation J Biol Chem 276 2001 49289 49298
29. I. Saltz, M. Rubin, and H. Hochster Cetuximab plus irinotecan is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor Proc Am Soc Clin Oncol 20 3a 2001 [Abstract 7]
30. M.J. Morin From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumour and anti-angiogenic agents Oncogene 19 2000 6574 6583